Keywords
Infertility
Goserelin
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To report the case of a young patient with multiple symptomatic uterine leiomyomas, managed conservatively with goserelin acetate (Zoladex®). Case details: A 28-year-old nulliparous female patient presented with abnormal uterine bleeding, pelvic pain, and a diagnosis of multiple uterine myomatosis, with lesions classified between FIGO 2 and 5. At that time, pharmacological treatment with Zoladex® 10.8 mg was chosen, in two doses administered between August 2021 and March 2025. A satisfactory clinical response was observed, with a reduction in uterine volume from 553.2 cm³ to 94.3 cm³ (−82.95%) and improvement in symptoms, without the need for immediate surgery. After follow-up with new consultations, it was noticeable that the adverse effects were mild and controllable, allowing treatment to continue. Final considerations: The case shows that goserelin is an effective and safe alternative for tumor reduction and symptomatic control in patients with uterine myomatosis and gestational desire, constituting a promising conservative strategy when immediate surgery is undesirable or contraindicated.
References
BRASILEIRO FILHO G. Bogliolo Patologia. 9 ed. Rio de Janeiro: Guanabara Koogan, 2016; 2038p.
CIEBIERA M, et al. GnRH agonists and antagonists in therapy of symptomatic uterine fibroids–current roles and future perspectives. Expert Opinion on Pharmacotherapy, v. 24, n. 16, p. 1799–1809, 2023.
DOLMANS MM,et al. Conservative management of uterine fibroid-related heavy menstrual bleeding and infertility: time for a deeper mechanistic understanding and an individualized approach. Journal of Clinical Medicine, v. 10, n. 19, p. 4389, 2021.
DONNEZ J, et al. Uterine fibroid–related infertility: mechanisms and management. Fertility and Sterility, 1 mar. 2024.
DONNEZ J, DOLMANS MM. Uterine fibroid management: from the present to the future. Human Reproduction Update, v. 22, n. 6, p. 665–686, 27 jul. 2016.
DONNEZ J. Uterine fibroids and progestogen treatment: lack of evidence of its efficacy: a review. Journal of Clinical Medicine, v. 9, n. 12, p. 3948, 2020.
FAVILLI A,et al. The challenge of FIGO type 3 leiomyomas and infertility: exploring therapeutic alternatives amidst limited scientific certainties. International Journal of Gynaecology and Obstetrics, v. 165, p. 976–987, 27 nov. 2023.
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES (EUA). Gonadotropin releasing hormone (GnRH) analogues. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, 2012.
GURUSAMYKS, et al. Medical therapies for uterine fibroids–a systematic review and network meta-analysis of randomised controlled trials. PLoS One, v. 11, n. 2, p. e0149631, 2016.
HAURANI APB, et al. Análise do tratamento com dose única do análogo do GnRH (acetato de gosserrelina 10,8 mg) em pacientes com leiomiomatose uterina atendidas no ambulatório de ginecologia endócrina de um hospital terciário de Curitiba. Arquivos Médicos dos Hospitais e da Faculdade de Ciências Médicas da Santa Casa de São Paulo, p. 1–8, 2021.
KUZNETSOVA MV, et al. Novel approaches to possible targeted therapies and prophylaxis of uterine fibroids. Diseases, v. 11, n. 4, p. 156, 1 nov. 2023.
LEE JH e CHOI YS. The role of gonadotropin-releasing hormone agonists in female fertility preservation. Clinical and Experimental Reproductive Medicine, v. 48, n. 1, p. 11, 2021.
LIANG Y,et al. Multicenter, prospective, single-arm clinical study to investigate the efficacy and safety of Zoladex (goserelin acetate) 10.8 mg prior to surgery in Chinese premenopausal women with symptomatic uterine fibroids. Gynecological Endocrinology, v. 40, n. 1, 3 dez. 2024.
MCWILLIAMS MM, CHENNATHUKUZHI VM. Recent advances in uterine fibroid etiology. Seminars in Reproductive Medicine, v. 35, n. 2, p. 181–189, 1 mar. 2017.
MICIĆ J, et al. Currently available treatment modalities for uterine fibroids. Medicina, v. 60, n. 6, p. 868, 26 maio 2024.
MILLER RM, FRANK RA. Zoladex® (goserelin) in the treatment of benign gynaecological disorders: an overview of safety and efficacy. BJOG: An International Journal of Obstetrics & Gynaecology, v. 99, n. s7, p. 37–41, fev. 1992.
MOHAMMED NH, et al. Evaluation of goserelin effectiveness based on assessment of inflammatory cytokines and symptoms in uterine leiomyoma. International Journal of Clinical Pharmacy, v. 42, n. 3, p. 931–937, 29 abr. 2020.
OLIVEIRA GMR. Avaliação da satisfação das pacientes com diagnóstico de leiomiomatose uterina tratadas com acetato de gosserrelina. Dissertação de Mestrado (Mestrado em Tocoginecologia e Saúde da Mulher) – Universidade Federal do Paraná, Curitiba, 2019; 77p.
PASTE VAP. Leiomiomatose e gestação: revisão de literatura. Monografia (Programa de Residência Médica em Ginecologia e Obstetrícia) – Hospital Universitário Cassiano Antônio Moraes, Universidade Federal do Espírito Santo, Vitória, 2021; 36p.
PROTA F, et al. Análise de custo-utilidade da gosserrelina no tratamento de pacientes com leiomioma: uma perspectiva do Sistema Único de Saúde. Jornal Brasileiro de Economia da Saúde, v. 16, n. 1, p. 16–24, 2024.
REIS FM, et al. Hormones and pathogenesis of uterine fibroids. Best Practice & Research Clinical Obstetrics & Gynaecology, v. 34, p. 13–24, jul. 2016.
SENRA JC. Preservação da fertilidade com o uso do agonista de GnRH em mulheres submetidas à quimioterapia para tratamento de linfoma: revisão sistemática com metanálise. Dissertação de Mestrado (Mestrado em Ginecologia e Obstetrícia) – Faculdade de Medicina da Universidade Federal de Minas Gerais, Belo Horizonte, 2016; 92p.
SILVA ALA, et al. Effect of goserelin in quality of life of women with abnormal uterine bleeding and leiomyoma: a case series. Brazilian Journal of Health Review, v. 6, n. 1, p. 715–727, 2023.
STEWART E,et al. Epidemiology of uterine fibroids: a systematic review. BJOG: An International Journal of Obstetrics & Gynaecology, v. 124, n. 10, p. 1501–1512, 13 maio 2017.
TU W, et al. Smooth muscle tumors of the uterus at MRI: focus on leiomyomas and FIGO classification. Radiographics, v. 43, n. 6, 1 jun. 2023.
VANNUCCINI S, et al. The modern management of uterine fibroids-related abnormal uterine bleeding. Fertility and Sterility, v. 122, n. 1, p. 20–30, 1 jul. 2024.
VEM JV, et al. Differential effect of gonadotropin-releasing hormone analogue treatment on estrogen levels and sulfatase activity in uterine leiomyoma and myometrium. Fertility and Sterility, v. 77, n. 6, p. 1227–1232, 1 jun. 2002.
VILOS GA, et al. The management of uterine leiomyomas. Journal of Obstetrics and Gynaecology Canada: JOGC, v. 37, n. 2, p. 157–178, 1 fev. 2015.